The significance of non-human primates as preclinical models of human arthritic disease

Expert Opinion on Drug Discovery

Volumn 3, Issue 3, 2008, Pages 299-310

  Vierboom, Michel ^a   Breedveld, Elia ^a   Kondova, Ivanela ^a   't Hart, Bert A ^a,b  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Animal models; Biologicals; Biomarkers; Collagen induced arthritis; Non human primates

Indexed keywords

ALKALINE PHOSPHATASE; BETA INTERFERON; BETA1A INTERFERON; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; COLLAGEN; CYCLOSPORIN A; DACLIZUMAB; ETANERCEPT; GANCICLOVIR; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; RECOMBINANT BETA INTERFERON;

ANIMAL TESTING ALTERNATIVE; BONE DEVELOPMENT; BONE EROSION; DISEASE COURSE; DISEASE MODEL; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG BINDING; DRUG INHIBITION; DRUG SCREENING; GENETIC SUSCEPTIBILITY; IMMUNOMODULATION; IMMUNOREACTIVITY; NONHUMAN; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RHESUS MONKEY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SPECIES COMPARISON;

EID: 41149176501     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.3.299     Document Type: Review

References (74)

1. Jacobson DL, Gange SJ, Rose NR, et al. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997;84(3):223-43
2. Wierda D, Smith HW, Zwickl CM. Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology 2001;158(1-2):71-4
3. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54(3):711-5
4. Bach JF, Fracchia GN, Chatenoud L. Safety and efficacy of therapeutic monoclonal antibodies in clinical therapy. Immunol Today 1993;14(9):421-5
5. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353(4):369-74
6. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990;49(4):697-702
7. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355(10):1018-28
8. Booth B, Zemmel R. Prospects for productivity. Nat Rev Drug Discov 2004;3(5):451-6
9. Frantz S. FDA publishes analysis of the pipeline problem. Nat Rev Drug Discov 2004;3(5):379
10. Mervis J. Productivity counts - but the definition is key. Science 2005;309(5735):726
11. Cuatrecasas P. Drug discovery in jeopardy. J Clin Invest 2006;116(11):2837-42
12. Bertino J. The mechanism of action of the folate antagonist in man. Cancer Res 1963;23:1286-306
13. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003;63(8):803-43
14. Gluck T, Opal SM. Advances in sepsis therapy. Drugs 2004;64(8):837-59
15. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330(6149):662-4
16. Nuremberg Code. Trials of War Criminals before the Nuremberg Military tribunals. Control Council Law No. 10. Washington DC Government Printing Office. 1949; Available at: http://ohsr.od.nih.gov/guidelines/ nuremberg.html
17. Helsinki Do. Declaration of Helsinki (2000 version). 1964; Available at: http://www.wma.net/e/policy/b3html
18. "The FDA animal efficacy rule". 2002; Available at: http://www.hhs.gov/nvpo/policy_reg.html
19. Guidance for Industry: Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA). 1999; Available at: http://www.fda.gov/cber/gdlns/rheumcln.pdf
20. Non-Human Primate Immune Tolerance Cooperative Study Group. 2001; Available at: http://grants.nih.gov/grants/guide/rfa-files/ RFA-AI-01-006.html
21. Holmdahl R, Bockermann R, Backlund J, et al. The molecular pathogenesis of collagen-induced arthritis in mice - a model for rheumatoid arthritis. Ageing Res Rev 2002;1(1):135-47
22. Kannan K, Ortmann RA, Kimpel D. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 2005;12(3):167-81
23. Olofsson P, Holmdahl R. Pristane-induced arthritis in the rat. Methods Mol Med 2007;136:255-68
24. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10(13):4025-31
25. Niki Y, Yamada H, Seki S, et al. Macrophage-and neutrophil-dominant arthritis in human IL-1 alpha transgenic mice. J Clin Invest 2001;107(9):1127-35
26. Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000;191(2):313-20
27. Hang L, Theofilopoulos AN, Dixon FJ. A spontaneous rheumatoid arthritis-like disease in MRL/1 mice. J Exp Med 1982;155(6):1690-701
28. Kamogawa J, Terada M, Mizuki S, et al. Arthritis in MRL/1pr mice is under the control of multiple gene loci with an allelic combination derived from the original inbred strains. Arthritis Rheum 2002;46(4):1067-74
29. Sakaguchi S, Sakaguchi N. Animal models of arthritis caused by systemic alteration of the immune system. Curr Opin Immunol 2005;17(6):589-94
30. Matsuno H, Yudoh K, Uzuki M, et al. The SCID-HuRAg mouse as a model for rheumatoid arthritis. Mod Rheumatol 2001;11:6-9
31. Pierer M, Muller-Ladner U, Pap T, et al. The SCID mouse model: novel therapeutic targets - lessons from gene transfer. Springer Semin Immunopathol 2003;25(1):65-78
32. Weyand CM. New insights into the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2000;39(Suppl 1):3-8
33. Arnett HA, Viney JL. Considerations for the sensible use of rodent models of inflammatory disease in predicting efficacy of new biological therapeutics in the clinic. Adv Drug Deliv Rev 2007;59(11):1084-92
34. Bendele A. Animal models of rheumatoid arthritis. J Musculoskelet Neuronal Interact 2001;1(4):377-85
35. Klareskog L, McDevitt H. Rheumatoid arthritis and its animal models: the role of TNF-alpha and the possible absence of specific immune reactions. Curr Opin Immunol 1999;11(6):657-62
36. Lindqvist A-K, Bockermann R, Johansson A, et al. Mouse models for rheumatoid arthritis. Trends Genet 2002;18(6):S7-13
37. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004;172(5):2731-8
38. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003;111(12):1887-95
39. Sachs DH. Tolerance: Of mice and men. J Clin Invest 2003;111(12):1819-21
40. 't Hart BA, Elferink DG, Drijfhout JW, et al. Liposome-mediated peptide loading of MHC-DR molecules in vivo. FEBS Lett 1997;409(1):91-5
41. 't Hart BA, Losen M, Brok HPM, et al. Chronic Diseases. In: The Laboratory Primate. Wolfe-Coote SP, editor. Elsevier Science, Amsterdam; 2004
42. Bontrop RE, Elferink DG, Otting N, et al. Major histocompatibility complex class II-restricted antigen presentation across a species barrier: conservation of restriction determinants in evolution. J Exp Med 1990;172(1):53-9
43. Bontrop RE, Otting N, de Groot NG, et al. Major histocompatibility complex class II polymorphisms in primates. Immunol Rev 1999;167:339-50
44. Geluk A, Elferink DG, Slierendregt BL, et al. Evolutionary conservation of major histocompatibility complex-DR/peptide/T cell interactions in primates. J Exp Med 1993;177(4):979-87
45. Bakker NP, van Erck MG, Zurcher C, et al. Experimental immune mediated arthritis in rhesus monkeys. A model for human rheumatoid arthritis? Rheumatol Int 1990;10(1):21-9
46. Terato K, Arai H, Shimozuru Y, et al. Sex-linked differences in susceptibility of cynomolgus monkeys to type II collagen-induced arthritis. Evidence that epitope-specific immune suppression is involved in the regulation of type II collagen autoantibody formation. Arthritis Rheum 1989;32(6):748-58
47. Bakker NP, van Erck MG, Botman CA, et al. Collagen-induced arthritis in an outbred group of rhesus monkeys comprising responder and nonresponder animals. Relationship between the course of arthritis and collagen-specific immunity. Arthritis Rheum 1991;34(5):616-24
48. Bakker NP, van Erck MG, Otting N, et al. Resistance to collagen-induced arthritis in a nonhuman primate species maps to the major histocompatibility complex class I region. J Exp Med 1992;175(4):933-7
49. Otting N, Heijmans CM, Noort RC, et al. Unparalleled complexity of the MHC class I region in rhesus macaques. Proc Natl Acad Sci USA 2005;102(5):1626-31
50. Vierboom MP, Jonker M, Bontrop RE, et al. Modeling human arthritic diseases in nonhuman primates. Arthritis Res Ther 2005;7(4):145-54
51. Janssens AC, Steyerberg EW, Jiang Y, et al. Value of the HLA-DRB1 shared epitope for predicting radiographic damage in rheumatoid arthritis depends on the individual patient risk profile. J Rheumatol 2006;33(12):2383-9
52. Klareskog L, Padyukov L, Lorentzen J, et al. Mechanisms of disease: genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nat Clin Pract Rheumatol 2006;2(8):425-33
53. Vierboom MP, Jonker M, Tak PP, et al. Preclinical models of arthritic disease in non-human primates. Drug Discov Today 2007;12(7-8):327-35
54. 't Hart BA, Bank RA, JA DR, et al. Collagen-induced arthritis in rhesus monkeys: evaluation of markers for inflammation and joint degradation. Br J Rheumatol 1998;37(3):314-23
55. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31(3):315-24
56. Ou LS, See LC, Wu CJ, et al. Association between serum inflammatory cytokines and disease activity in juvenile idiopathic arthritis. Clin Rheumatol 2002;21(1):52-6
57. Rooney M, David J, Symons J, et al. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 1995;34(5):454-60
58. Myers LK, Higgins GC, Finkel TH, et al. Juvenile arthritis and autoimmunity to type II collagen. Arthritis Rheum 2001;44(8):1775-81
59. Turner S, Bakker NP, 't Hart BA, et al. Identification of antibody epitopes in the CB-11 peptide of bovine type II collagen recognized by sera from arthritis-susceptible and-resistant rhesus monkeys. Clin Exp Immunol 1994;96(2):275-80
60. 't Hart BA, Bakker NP, Jonker M, et al. Resistance to collagen-induced arthritis in rats and rhesus monkeys after immunization with attenuated type II collagen. Eur J Immunol 1993;23(7):1588-94
61. Morgan K, Clague RB, Shaw MJ, et al. Native type II collagen-induced arthritis in the rat: the effect of complement depletion by cobra venom factor. Arthritis Rheum 1981;24(11):1356-62
62. Pettit AR, Ji H, von Stechow D, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159(5):1689-99
63. Bakker NP, Van Besouw N, Groenestein R, et al. The anti-arthritic and immunosuppressive effects of cyclosporin A on collagen-induced arthritis in the rhesus monkey. Clin Exp Immunol 1993;93(3):318-22
64. Brok HP, Tekoppele JM, Hakimi J, et al. Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys. Clin Exp Immunol 2001;124(1):134-41
65. Vierboom MP, Zavodny PJ, Chou CC, et al. Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis Rheum 2005;52(2):627-36
66. Goossens PH, Schouten GJ, 't Hart BA, et al. Feasibility of adenovirus-mediated nonsurgical synovectomy in collagen-induced arthritis-affected rhesus monkeys. Hum Gene Ther 1999;10(7):1139-49
67. Kraan MC, Versendaal H, Jonker M, et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 1998;41(8):1481-8
68. Tak PP, Hart BA, Kraan MC, et al. The effects of interferon beta treatment on arthritis. Rheumatology (Oxford) 1999;38(4):362-9
69. van Holten J, Pavelka K, Vencovsky J, et al. A multicentre, randomised, double blind, placebo controlled Phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64(1):64-9
70. Bakker NP, van Erck MG, 't Hart LA, et al. Acquired resistance to type II collagen-induced arthritis in rhesus monkeys is reflected by a T cell low-responsiveness to the antigen. Clin Exp Immunol 1991;86(2):219-23
71. 't Hart B, Jagessar S, Kap Y, et al. Preclinical models of multiple sclerosis in nonhuman primates. Expert Rev Clin Immunol 2007;3(5):749-61
72. 't Hart B, Amor S, Jonker M. Evaluating the validity of animal models for research into therapies for immune-based disorders. Drug Discov Today 2004;9(12):517-24
73. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22(2):151-85
74. Frank RG. New estimates of drug development costs. J Health Econ 2003;22(2):325-30